TrumpRx promised a supermarket for cheaper drugs but delivered a boutique

President Trump launched the TrumpRx website in February with the goal of lowering prescription drug costs for Americans. The platform was presented as a significant development in healthcare, but an analysis of the site reveals a different picture. While the administration touted 92 deals on brand-name drugs from various pharmaceutical companies, these offerings cover less than 12% of the brand-name medications produced by those participating firms.

Many common and high-revenue drugs are missing from the platform, including treatments for serious conditions like cancer and HIV. Researchers note that participating companies are selective about which products they offer for discount, focusing on a limited number of items rather than providing a broad catalog of affordable medicine. In some instances, generic versions of these drugs are already available at lower prices through other channels.

While the site does provide some utility, particularly for patients paying out-of-pocket for drugs not covered by insurance, it does not function as the comprehensive marketplace that was initially promised. The administration has struggled to provide updated data on how many patients have successfully used the site, and experts suggest that insured patients often find cheaper alternatives through their existing coverage and pharmacy benefits.

Ultimately, the platform serves more as a boutique collection of specific discounts than a major shift in the pharmaceutical market. With many major drugs excluded, the reach of the project remains narrow, leaving many consumers to rely on traditional pharmacy discounts and standard insurance pathways to manage their healthcare expenses.